IL1A and diabetic kidney disease: In a phase I study, participants with diabetic kidney disease received dasatinib and quercetin (100 mg and Q 1000 mg) for three days, and a reduction in senescent adipocytes (p16 ink4a and β-gal positive cells) and serum senescence markers, such as IL-1α, IL-2, IL-6, IL-9, and MMP-2, 9, and 12, was registered [32].